Like many developing countries, Vietnam has tended to exclude first and second (or subsequent) medical use inventions from patent protection in order to reduce drug prices. The patent office has interpreted current Vietnamese regulations as not including use inventions, including medical use inventions, and thus has objected to patent applications for such inventions. However, an examination of the regulations reveals some different results.

Vietnam’s Drug Distribution PolicyUnder its WTO commitments, Vietnam agreed to allow foreign-invested entities (FIEs) to conduct distribution services (i.e., commission agent, wholesale, and retail services) for most types of products, but it specifically excluded “pharmaceutical products and drugs.” Consequently, foreign pharmaceutical producers typically establish legal presence in Vietnam by way of representative offices through which they can conduct marketing activities, and use local drug distributors to conduct sales and delivery of their products.

To ensure harmony in regulations between ASEAN countries as well as tighten the management of drug registration, the Ministry of Health (MOH) issued Circular No. 44/2014/TT-BYT dated November 25, 2014, on Registration of Drugs (Circular 44) to replace its previous Circular No. 22/2009/TT-BYT (Circular 22) dated November 24, 2009. Circular 44 took effect on January 15, 2015. Among the contents of Circular 44, there are four main points changed from Circular 22:

Patents play a key role in encouraging the development of pharmaceutical products. It can take several hundred million dollars to discover, develop, and gain regulatory approval for a new drug, and funding for research is obtained primarily from profits made while the innovators have exclusive rights to market their medicines. The length of this exclusivity is therefore an important aspect of patent policy for pharmaceuticals.

As a developing country with a large population, Vietnam has long viewed parallel imports as an effective antidote to the high price of innovator drugs. The parallel importation of medicines for the prevention and treatment of human diseases is permitted, and even encouraged, under Vietnamese law. Many pharmaceutical manufacturers, however, are understandably concerned that parallel importation could lead to diminished profits, thereby reducing research and development efforts, and leading to a slowdown in the innovation of new drugs.

The 2015 edition of Media, Advertising, and Entertainment Law Throughout the World, a concise and current overview of media, advertising, entertainment, and art law in more than 30 countries worldwide, has been published. Lawyers at Tilleke & Gibbins contributed both the Thailand and Vietnam chapters to the guide. The Thailand chapter covers the following main topics:

Media, Advertising, and Entertainment Law Throughout the World 2015  has been published, and Tilleke & Gibbins has contributed the Thailand and Vietnam chapters of the guide. Jim Dao, Giang Thi Huong Tran, and Tu Ngoc Trinh jointly authored the Vietnam chapter, which delves into media law, advertising law, entertainment law, and art law.

To promote and develop Thailand’s growing insurance industry and prepare for greater market activity under the Asean Economic Community, the government recently amended the laws governing the country’s life and non-life insurance industries for the third time. Formally known as the Life Insurance Act No. 3 of 2015 and the Non-Life Insurance Act No. 3 of 2015, the amendments took effect on March 6, seven years after the previous amendments were made. The changes can be divided into three main parts as follows: